JAK2 levels in balding and non-balding scalp before and after topical minoxidil
Official title: Assessment of Janus Kinase 2 Expression in Patients With Androgenic Alopecia and Its Modulation by Topical Minoxidil Therapy.
Run by Kasr El Aini Hospital · NCT07563036 · Data updated 2026-11-12
This will test whether three months of topical minoxidil changes JAK2 protein levels in the scalps of adults (18–50) with mild to moderate androgenetic alopecia.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | Men only |
| Enrollment | 25 (estimated) |
| Sponsor | Kasr El Aini Hospital Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Cairo, Cairo Governorate) |
| Status | Recruiting |
| Started | February 1, 2026 |
| Main results expected | October 1, 2026 |
| Study ends | January 1, 2027 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT07563036 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Male adults aged 18–50 with mild to moderate androgenetic alopecia (Hamilton-Norwood II–V), treatment-naive or able to complete a short washout, and willing to consent to scalp biopsies and follow-up visits.
✕Probably not a fit
People with other types of hair loss, active inflammatory scalp disease, recent systemic immunosuppression, major systemic illness, bleeding disorders, or unwilling to undergo scalp biopsies are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective single-arm pre–post study enrolling 25 adults with mild to moderate androgenetic alopecia at Kasr El Aini Hospital. At baseline participants have clinical evaluation, standardized photography, trichoscopy, and two 2 mm punch biopsies taken from balding and non-balding scalp. Participants then apply topical minoxidil 5% for three months (1 cc twice daily for men, once daily for women) and a third biopsy is taken from the balding area after treatment. Tissue JAK2 protein levels will be measured by ELISA and correlated with trichoscopic measures of clinical response.
Why it matters
Potential benefit: If successful, the study could identify a biological marker linked to hair loss and treatment response that helps guide future therapies.
How similar studies have gone: Minoxidil's clinical benefit in androgenetic alopecia is established, but measuring changes in tissue JAK2 in this condition is relatively novel while JAK pathway work has been more prominent in alopecia areata.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male adults aged 18 to 50 years with androgenetic alopecia. * Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V. * Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month. * Willing and able to provide written informed consent. Exclusion Criteria: * Other types of hair loss, including inflammatory or scarring alopecia. * Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis. * Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months. * History of severe systemic disease, including renal, cardiovascular, or hepatic disease. * Chemotherapy during the last 5 years. * Bleeding disorders.
Where it's running
-
Kasr El Aini Hospital
Cairo, Cairo Governorate, Egypt Recruiting
Study contacts
- Study coordinator: Heba Ahmed
- Email: heba.a.abdelgayed@kasralainy.edu.eg
- Phone: +201016532351
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PP405 0.05% topically applied gel for adult men with pattern hair loss
A topical gel called PP405 is being tested in adult men with androgenetic alopecia to see if it can help with hair growth and is safe over a year.
-
Dual treatment with KeraFactor and Revian LED for female pattern hair loss
This study tests whether using a scalp-stimulating serum together with a Revian LED cap helps women with androgenic alopecia grow more hair than each treatment alone or placebo.
-
Two hair supplements for men with androgenic alopecia
This study tests two daily hair supplement formulations against placebo to see if they improve hair growth and perceived hair quality in men with mild to moderate androgenetic alopecia over 84 days.
-
EPI-001 for androgenetic alopecia in adults
This early-phase study tests autologous dermal papilla cell therapy (EPI-001) to see if it is safe and can help hair grow in people with androgenetic alopecia.
-
2-Deoxy-D-ribose hydrogel versus 5% minoxidil for androgenetic alopecia
This trial will test whether a once-daily topical 2‑Deoxy‑D‑ribose hydrogel is as effective and safe as 5% minoxidil for adults aged 18 to 50 with mild to moderate androgenetic alopecia.
-
TH07 topical treatment for male pattern hair loss
This trial will test whether a new daily topical spray called TH07 helps men aged 18–49 with male pattern hair loss grow more hair than standard minoxidil or a placebo over 24 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.